UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,566	08/29/2006	Rorbert C. Moschel	253443	3649
	7590 11/15/2007 Γ & MAYER, LTD.	EXAMINER		
TWO PRUDEN	NTIAL PLAZA, SUITE 4	JAISLE, CECILIA M		
CHICAGO, IL	STETSON AVENUE _ 60601-6731		ART UNIT	PAPER NUMBER
-			1624	
			MAIL DATE	DELIVERY MODE
			11/15/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	•				
		Application No.	. Applicant(s)		
		10/585,566	MOSCHEL ET AL.		
	Office Action Summary	Examiner	Art Unit		
		Cecilia M. Jaisle	1624		
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet	with the correspondence address		
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING D. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. Depriod for reply is specified above, the maximum statutory period the period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN 36(a). In no event, however, may will apply and will expire SIX (6) Mo o, cause the application to become	IICATION. a reply be timely filed DNTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).		
Status	•	•			
1)⊠	Responsive to communication(s) filed on 06 J	uly 2006.			
	This action is FINAL. 2b) ☑ This action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C	D. 11, 453 O.G. 213.		
Disposit	ion of Claims		:		
5)□ 6)⊠ 7)⊠	Claim(s) 1-17,31,32,40 and 41 is/are pending 4a) Of the above claim(s) 16,17,31,32,40 and 4 Claim(s) is/are allowed. Claim(s) 1-4 and 10-15 is/are rejected. Claim(s) 5-9 is/are objected to. Claim(s) are subject to restriction and/o	4 <u>1</u> is/are withdrawn from	consideration.		
Applicat	ion Papers	·			
10)⊠	The specification is objected to by the Examine The drawing(s) filed on <u>06 July 2006</u> is/are: a) Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine The specification is objected to be specification.	☑ accepted or b)☐ objording(s) be held in abeytion is required if the drawing	ance. See 37 CFR 1.85(a). ng(s) is objected to. See 37 CFR 1.121(d).		
Priority (under 35 U.S.C. § 119				
12)□ a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea See the attached detailed Office action for a list	s have been received. s have been received in rity documents have bee u (PCT Rule 17.2(a)).	Application No en received in this National Stage		
A44 m = b	,4(a)	•			
Attachmer 1) Notice	nt(s) ce of References Cited (PTO-892)	4) 🗍 Interviev	v Summary (PTO-413)		
2) Notic	ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08)	Paper N	o(s)/Mail Date: f Informal Patent Application		
	er No(s)/Mail Date <u>08-29-2006</u> .	6) Other: _			

DETAILED OFFICE ACTION

Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15, drawn to compounds of Formula I, classified in class 544, subclasses 258 and 259, and their pharmaceutical compositions, classified in class 514, subclass 249.
- II. Claims 16, 17, 31, 32, 40 and 41, drawn to pharmaceutical methods using Group I compounds and compositions, classified in class 514, subclass 249.

The inventions are independent or distinct for the following reasons. Inventions I – II, respectively, are not obvious variants of each other, i.e., a reference that could be used to reject one invention could not be used to reject another invention; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j).

In the instant case, Group I compounds are distinct from Group II methods, because Group I compounds would be expected to have different utilities. For example, Group I compounds would be expected to be useful to treat tumor cells (US 5929046).

In the instant case, the related Groups I–II inventions do not overlap in scope because the inventions have acquired separate status, as evidenced by their separate classification in the art. Although some of these Groups may have the same patent classification, they would each require a separate search in the literature. Therefore, it

would impose an undue burden on the examiner to search and examine these distinct inventions together.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

- (a) the inventions have acquired a separate status in the art in view of their different classification;
- (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
- (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries; see MPEP § 808.02);
- (d) the prior art applicable to one invention would not likely be applicable to another invention:
- (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that a complete reply to this requirement <u>must</u> include

(i) election of a invention to be examined though the requirement be traversed (37

CFR 1.143) and (ii) identification of claims encompassing the elected invention.

During a telephone conversation with Mr. Xavier Pillai on Oct. 5, 2007 a provisional election was made with traverse to prosecute the invention of Group I,

Application/Control Number: 10/585,566

Art Unit: 1624

claims 1-15. Applicant must affirm this election in replying to this Office action. Claims 31, 32, 40 and 41 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. If the reply does not distinctly and specifically point out supposed errors in the restriction and election of species requirements, the election shall be treated as without traverse.

Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product claims (Group I) and method claims (Group II). Where applicant elects claims directed to the product, and product claims are subsequently found allowable, withdrawn method claims that depend

Art Unit: 1624

from or otherwise require all limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected method invention must require all the limitations of an allowable product claim for that method invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined claims will be withdrawn, and the rejoined claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and method claims may be maintained. Withdrawn claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the method claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the examiner withdraws the restriction requirement before the patent issues. See MPEP § 804.01.

Rejections Under 35 USC 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- Resolving the level of ordinary skill in the pertinent art. 3.
- Considering objective evidence present in the application indicating 4. obviousness or nonobviousness.

Claims 1-4 and 10-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over McMurry, et al., US 5929046, issued 19990727, describing RN 192441-15-9, 2-Pteridinamine, 4-[(4-bromo-2-thienyl)methoxy]-; RN 192441-17-1, 2-Pteridinamine, 4Application/Control Number: 10/585,566

Art Unit: 1624

[(4-fluorophenyl)methoxy]-, and RN 286941-18-2, 2-Pteridinamine, 4-[(4-chlorophenyl)methoxy]-, useful for treating tumor cells. These are some of the compounds excluded by the proviso in claim 1 that "R1 and R2 are not simultaneously hydrogen." However, compounds of present Formula I wherein R1 and/or R2 are lower alkyl are obviously suggested by the McMurry compounds as homologs thereof.

It would have been obvious to one of ordinary skill in the art at the time the present invention was made to modify the compounds of McMurry to prepare the alkyl homologs and position isomers thereof. One of ordinary skill in the art would have been motivated to prepare the instantly claimed compounds because such structurally homologous and isomeric compounds are expected to possess similar properties to the compounds of McMurry. It has been held that compounds that are structurally homologous and isomeric to prior art compounds are *prima facie* obvious, absent a showing of unexpected results.

An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties.

In re Payne, 203 USPQ 245, 254 (CCPA 1979). See In re Papesch, 137 USPQ 43 (CCPA 1963) and In re Dillon, 16 USPQ2d 1897 (Fed.Cir. 1991) (discussed in MPEP § 2144) for an extensive case law review of obviousness based on close structural chemical compound similarity. See MPEP § 2144.08, ¶ II.A.4(c). Compounds which are homologs (compounds differing regularly by the successive addition or subtraction of the same chemical group, e.g., by -CH3 or lower alkyl groups), as here, are generally

Application/Control Number: 10/585,566

Art Unit: 1624

of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. *In re Wilder*, 195 USPQ 426 (CCPA 1977).

Objected Claims

Claims 5-9 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cecilia M. Jaisle, J.D. whose telephone number is 571-272-9931. The examiner can normally be reached on Monday through Friday; 8:30 am through 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson, can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. If you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Cecilia M. Jaisle, J.D.

10/12/2007

JAINES O. WILSON

SUPERVISORY PATENT EXAMINER